The first subject received the highest dose of 20M cells in Asterias Biotherapeutics� $AST Phase 1/2a Clinical Trial, labeled as SCiSTAR, evaluating AST-OPC1 (oligodendrocyte progenitor cells) in patients with complete cervical spinal cord injury. The purpose of the dose escalation is to build a thorough safety profile before advancing to 2a phase.